Alks stock zacks
ALKS: Alkermes plc - Zacks Investment Research ALKS: Alkermes plc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Alkermes plc from Zacks Investment Research Should I buy Alkermes Plc (ALKS) - Zacks Alkermes plc - Buy. Zacks' proprietary data indicates that Alkermes plc is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ALKS shares relative to the ALKS Stock Price, Forecast & News (Alkermes) | MarketBeat Here are some recent quotes from research analysts about Alkermes stock: 1. According to Zacks Investment Research, "Alkermes reported impressive third-quarter results wherein both earnings and sales beat estimates. With increasing traction of Aristada in the market, Alkermes is emerging as a leader in the treatment of schizophrenia.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALKS's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. Previous Close Today's High / Low 52 Week High / Low Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat ... Feb 13, 2020 · Alkermes plc (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not Alkermes (ALKS) Gains As Market Dips: What You Should Know ... Jan 10, 2020 · ALKS is currently a Zacks Rank #3 (Hold). Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Click to get this free report ALKS Stock Quote of Alkermes Plc - InvestorPlace Check out our ALKS stock analysis, current ALKS quote, charts, and historical prices for Alkermes Plc stock InvestorPlace Feature Writer Jan 12, From Zacks Investment Research Sep 24, 2019
Alkermes (ALKS) Down 8.6% Since Last Earnings ... - zacks.com
View Alkermes plc ALKS investment & stock information. Get the latest Alkermes plc ALKS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Alaska Air Group, Inc. - ALK - Stock Price Today - Zacks View Alaska Air Group, Inc. ALK investment & stock information. Get the latest Alaska Air Group, Inc. ALK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. All News for ALKS : Alkermes plc - Zacks.com
ALKS: Alkermes plc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Alkermes plc from Zacks Investment Research
ALKS: Alkermes plc Stock Quote & Analysis
LGND vs. ALKS: Which Stock Is the Better Value Option? Zacks Equity Research. 1/6/2020. Analysis: How Iowa Slipped Away From Joe Biden LGND sticks out from ALKS in both our Zacks Rank and
View Alaska Air Group, Inc. ALK investment & stock information. Get the latest Alaska Air Group, Inc. ALK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. All News for ALKS : Alkermes plc - Zacks.com Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know. by Zacks Equity Research Published on January 16,2020 ALKS: Alkermes plc - Brokerage Recommendations - Zacks.com ALKS: Alkermes plc broker recommendations. Get the latest broker recommendations from Zacks Investment Research. ALKS: Alkermes plc Stock Quote & Analysis
Real time Alkermes (ALKS) stock price quote, stock graph, news & analysis. Real time Alkermes (ALKS) stock price quote, stock graph, news & analysis. The Motley Fool helps millions of people ALKS Price Target and Analyst Ratings (Alkermes) | MarketBeat Nov 09, 2019 · Their average twelve-month price target is $22.42, suggesting that the stock has a possible upside of 58.76%. The high price target for ALKS is $28.00 and the low price target for ALKS is $16.00. There are currently 1 sell rating, 10 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold." Alkermes plc (ALKS) Interactive Stock Chart - Yahoo Finance Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review. The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020. Alkermes (ALKS) Down 8.6% Since Last Earnings ... - zacks.com